Advanced Breast Cancer Brain Metastasis
Conditions
Brief summary
A prospective, multicenter, observational cohort study to evaluate the efficacy and safety of a novel anti-tumor drug as a radiosensitizer in patients with advanced breast cancer brain metastasis.
Interventions
DRUGRadiotherapy + Novel Anti-tumor Drug
1. Novel anti-tumor drugs \[including: ADC drugs (such as T-DXd, T-DM1, etc.), CDK4/6 inhibitors, TKI drugs (such as Pyrotinib, Tucatinib, etc.), novel chemotherapy drugs (such as Utidelone, Irinotecan liposomes, etc.), Bevacizumab, PD-1/PD-L1 inhibitors, etc.\] 2. Radiotherapy
Sponsors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Males or females who are at least 18 years of age on the day of signing the informed consent form. 2. Patients with advanced breast cancer that is inoperable and has metastasized to the brain, confirmed by histology or cytology. 3. Patients who are planned to receive, currently receiving, or have completed intracranial radiotherapy after discussion by a multidisciplinary team (MDT) at the stage of brain metastasis. 4. Patients who are planned or currently receiving a systemic treatment regimen with a novel anti-tumor drug selected by the physician, within 3 weeks before radiotherapy, during radiotherapy, or within 3 weeks after completion of radiotherapy. These drugs include: ADC drugs (such as T-DXd, T-DM1, etc.), CDK4/6 inhibitors, TKI drugs (such as Pyrotinib, Tucatinib, etc.), Novel chemotherapy drugs (such as Utidelone, Irinotecan liposomes, etc.), Bevacizumab, PD-1/PD-L1 inhibitors, etc. 5. Patients with a traceable medical history during the treatment period. 6. Patients who are able to sign the informed consent form to participate in the study.
Exclusion criteria
1. The subject has leptomeningeal metastasis. 2. If the patient has concurrent brain metastasis, the neurological symptoms are too severe to cooperate with radiotherapy. 3. The subject has not signed the informed consent form. 4. Pregnant or breastfeeding women. 5. Other situations deemed by the investigator as unsuitable for inclusion in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Intracranial Progression-Free Survival | 24 months | The time from the randomization of the subject to the first documented tumor progression (PD) or death due to any cause. |
Countries
China
Contacts
CONTACTFei Ma, Professor
Outcome results
None listed